Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Pierre Van Damme, Paolo Bonanni, F Xavier Bosch, Elmar Joura, Susanne Krüger Kjaer, Chris J L M Meijer, Karl-Ulrich Petry, Benoit Soubeyrand, Thomas Verstraeten, Margaret Stanley
Author Information
Pierre Van Damme: Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium. Electronic address: pierre.vandamme@uantwerp.be.
Paolo Bonanni: Department of Health Sciences, University of Florence, Florence, Italy.
F Xavier Bosch: Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.
Elmar Joura: Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Susanne Krüger Kjaer: Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark.
Chris J L M Meijer: Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands.
Karl-Ulrich Petry: Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany.
Benoit Soubeyrand: Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France.
Thomas Verstraeten: P95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium.
Margaret Stanley: Department of Pathology, Cambridge University, Cambridge, UK.
With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.
